Search

Background: Obesity, well known as a risk factor for several diseases, can also lead to pelvic floor dysfunction (PFD). However, scant data are available regarding PFD in obese individuals. Our study was designed to assess the prevalence, severity, and the quality of life (QOL) effect of PFD in obese women before and after bariatric surgery at a university hospital in Italy. Methods: A total of 100 obese (body mass index [BMI] >= 30 kg/m(2)) women completed 6 validated specific and QOL questionnaires about PFD. The patients were evaluated by physical examination, endoanal ultrasonography, rectal balloon distension test, and dynamic magnetic resonance imaging. Of the 100 patients, 87 were reassessed 12 months after bariatric surgery. Results: The prevalence of PFD was 81%, and 49% of patients reported that their symptoms adversely affected their QOL. Urinary incontinence (UT) was the most common disorder (61%) and was associated with the BMI (P = .04). Fecal incontinence and pelvic organ prolapse symptoms were reported by 24 and 56 patients, respectively. Urogenital prolapse and rectocele was documented in 15% and 74% of patients, respectively. After a mean BMI reduction of 10 kg/m(2), the prevalence of PFD decreased to 48% (P = .02), with a significant improvement in QOL. The prevalence of UI decreased to 9.2% (P = .0001) and was associated with the decrease in postoperative BMI (P = .04). The rate of resolution of the symptoms was 84%, 85%, and 74% for UT, fecal incontinence, and pelvic organ prolapse, respectively. Conclusion: In the present sample of obese women, PFD was common and adversely affected their QOL. A clear association was found between the BMI and UT. Weight loss resulted in improved UI, fecal incontinence, and symptoms of pelvic organ prolapse. (Surg Obes Relat Dis 2013;9:69-76.) (C) 2013 American Society for Metabolic and Bariatric Surgery. All rights reserved.

Background: Cancer, perforation, and bleeding in the bypassed stomach after Roux-en-Y gastric bypass (RYGB) are rare, but serious, complications that need an early diagnosis. Our goal was to perform gastric bypass such that traditional endoscopic and radiographic study of the gastric remnant would be possible and, at the same time, obtain results in terms of weight loss equivalent to those found after standard RYGB. A previously published study demonstrated that complete occlusion of the gastrogastric outlet was not necessary to lose weight. We have developed an open RYGB-on-vertical banded gastroplasty procedure. Methods: Since 2002, 289 patients with a mean age of 40.1 14.8 years, mean body mass index of 51.4 7.3 kg/m2, and mean percentage of excess body weight of 107.3% 36.7% underwent RYGB-on-vertical banded gastroplasty as their primary procedure. Results: The follow-up examinations included radiographic and, if necessary, endoscopic studies at 6 and 12 months postoperatively and annually thereafter. Two cases of anastomotic ulcer were detected, one of which involved band erosion. The percentage of excess weight loss was 48.2% 18.8% after 6 months and 59.0% 17.7%, 63.3% 13.9%, 66.9% 17.5%, and 70.0% 17.7% after 1, 2, 3, and 4 years, respectively. The weight loss curve was similar to that for standard RYGB. Conclusion: The results of our study have shown that RYGB-on-vertical banded gastroplasty is as effective as traditional RYGB, while allowing for traditional radiography of the bypassed stomach in every patient. Endoscopy of the distal stomach and, therefore, the biliary tract, was also possible. These are the fundamental aspects of the procedure. (Surg Obes Relat Dis 2008;4: 16 –25.) © 2008 American Society for Metabolic and Bariatric Surgery. All rights reserved.

BACKGROUND: Our aim was to monitor the impact of Roux-en-Y gastric bypass (RYGBP) on body composition over a 24-month period by dual-energy X-ray absorptiometry (DXA). METHODS: Forty-one women (40.6 ± 10.0 years old; 42.6 ± 6.6 kg/m(2)) entering a bariatric surgery programme were submitted to whole-body DXA (Lunar iDXA) before treatment and after 3, 6, 12 and 24 months. Fat mass (FM), non-bone lean mass (LM), bone mineral content (BMC) and density (BMD) were measured at whole body and regionally. Android visceral adipose tissue (VAT) was estimated by a recently validated software. RESULTS: Twenty-nine patients (44.3 ± 11.8 years old; BMI, 45.4 ± 8.9 kg/m(2)) concluded the study. Following surgery, the progressive decrease of BMI was associated with reduced whole-body and regional FM. LM showed a moderate decrease at 3 months and stabilized thereafter. A progressive decrease of total FM/LM and android FM/LM ratios were observed in the 3- to 6-month (-19.1 ± 8.4 % and -26.5 ± 10.9 %, respectively; p

Background: The optimal dose of low molecular weight heparin (LMWH) to prevent venous thromboembolism (VTE) after bariatric surgery remains controversial. The aim of this multicentre, open-label, pilot study was to evaluate the efficacy and safety of two different doses of the LMWH parnaparin administered to patients undergoing bariatric surgery. Methods: Patients were randomised to receive 4,250 IU/day (group A) or 6,400 IU/day (group B) of parnaparin s.c. for 7-11 days. Bilateral colour Doppler ultrasound of the lower limb was performed before surgery and at the end of the treatment period. The primary efficacy outcome was a composite of asymptomatic and symptomatic deep vein thrombosis, symptomatic pulmonary embolism and death from any cause during treatment. The primary safety endpoint was major and clinically relevant non-major bleeding. Results: A total of 258 patients underwent randomization; 8 subjects were excluded following the safety analysis. One hundred thirty-one patients [106 females; mean age, 40.3 years (standard deviation (SD) ±9.6); mean body mass index (BMI), 44.6 kg/m2 (SD ±5.4)] were assigned to group A and 119 patients [93 females; mean age, 41.5 years (SD ±9.9); mean BMI, 44.2 kg/m2 (SD ±5.4)] were assigned to group B. The rate of the primary efficacy outcome was 1.5 % (two cases; 95 % confidence interval (CI), 0.2-6.0 %) in group A as compared with 0.8 % (one case; 95 % CI, 0.4-5.3 %) in group B (p = ns). The composite incidence of major bleeding and clinically relevant non-major bleeding was 6.1 % (eight cases; 95 % CI, 2.9-12.1 %) in group A and 5.0 % (six cases; 95 % CI, 2.1-11.1 %) in group B (p = ns). Conclusions: A parnaparin dose of 4,250 IU/day seems suitable for VTE prevention in patients undergoing bariatric surgery. © 2013 The Author(s).

Background The aims of this study are to evaluate the macroscopic and microscopic changes in the remnant stomach at mid-term follow-up of patients who underwent a Roux-en-Y gastric bypass on vertical banded gastroplasty (RYGB-on-VBG). The stomach could be reached through a 1.1-cm gastro-gastrostomy with an endoscope of standard size. Methods From January 2009 to July 2010, 51 asymptomatic patients at 4 and 5 years follow-up after RYGB-on-VBG submitted to upper endoscopy. All of them were examined with standard endoscopy with collection of biopsies in gastric fundus, body, and antrum. The macroscopic and microscopic findings were analyzed according to Sydney Classification. Results The endoscopy of the remnant stomach was technically easy and already showed on macroscopic examination 90 % cases of gastritis (41.2 % mild, 49 % severe) with tendency of severity in the distal stomach part. Histological analysis detected 39.2 % of active gastritis, 50.6 % of quiescent gastritis, 7.8 % of intestinal metaplasia, and 3.9 % of lymphoma-like gastritis. Conclusions The results surprised us. We found a very high rate of mucosa abnormalities after RYGB-on-VBG. All of the patients have to be regularly controlled in follow-up and treatment has to be introduced when needed. Again, we would like to ask the question: what is happening with the remnant stomach after standard RYGB, banded gastric bapass, or minigastric bypass? Did we reach the time to answer the question?